When you fill a prescription or get a drug at a hospital, you trust it's safe. For decades, the Food and Drug Administration (FDA) has acted as the gatekeeper, deciding which medications reach the market after testing and clinical trials. So most people assume that if a drug carries FDA approval, it's been thoroughly vetted and its risks are spelled out on the label. But what happens when an approved drug causes serious, unexpected harm? Can the company that made it point to federal approval and walk away?
That question sits at the center of pharmaceutical and product liability law. Drug makers have long argued that because a federal agency reviewed and approved their labels, lawsuits brought under state law should be thrown out. The argument leans on a doctrine called federal preemption, the idea that federal rules override conflicting state laws. For years, manufacturers used it to get injured patients' claims dismissed.
A single Supreme Court case reshaped that landscape. The Court took up whether a drug company is immune from state lawsuits simply because the FDA signed off on its warning label. Below, we break down what the Court decided, how failure-to-warn claims work, and what your options are if an approved medication seriously injured you.
What was Wyeth v. Levine?
Decided in 2009, Wyeth v. Levine is one of the most significant Supreme Court rulings on prescription drugs and product liability. It answered a direct question: does FDA approval stop an injured patient from suing a drug manufacturer under state law for failing to provide an adequate warning?
In a 6-3 decision, the Court held that it does not. FDA approval does not automatically preempt state-law failure-to-warn claims. The ruling confirmed that a manufacturer, not the FDA, carries the primary responsibility for the safety of its product and the accuracy of its label. Injured patients keep their right to seek compensation in state court when a drug company fails to warn doctors and the public about a known danger.
The facts behind the Wyeth v. Levine case
The case grew out of a devastating injury. On April 7, 2000, Diana Levine, a Vermont musician who played guitar, bass, and piano, went to her local clinic for a severe migraine and the nausea that came with it. She was treated with Demerol for pain and Phenergan, an antihistamine made by Wyeth, for the nausea.
Phenergan can be given several ways. Intramuscular injection is the preferred method because it carries almost no risk of hitting an artery. An IV-drip, where the drug is diluted in saline, is also considered safe when done correctly. The third method, "IV-push," forces the drug directly into the vein and carries the highest risk of artery involvement. Levine's first dose that day was given intramuscularly without incident. When her nausea persisted, a clinician gave her a second dose by IV-push.
That's where it went wrong. The drug reached an artery, and Levine developed severe, irreversible gangrene. Doctors amputated her right hand, then her forearm. The injury ended her career as a musician.
Here's the detail that drove the case: Phenergan's label did warn that arterial exposure could cause gangrene and amputation. Levine's argument wasn't that there was no warning at all. It was that the label should have told clinicians to avoid the riskier IV-push method, given what the company knew. And the company knew a lot. Levine presented evidence of at least 20 prior incidents in which a Phenergan injection led to gangrene and amputation. After the first came to Wyeth's attention back in 1967, the company worked with the FDA on the label, but as amputations kept happening over the years, it never added a stronger warning specific to IV-push.
She had already settled separately with the clinic and the clinician who gave the injection. A Vermont jury then found Wyeth liable and awarded roughly $6.7 million, later reduced to account for that earlier settlement. The Vermont Supreme Court upheld the verdict, and Wyeth took the case to Washington.
What is federal preemption in pharmaceutical litigation?
Wyeth's appeal rested on federal preemption. The doctrine comes from the Supremacy Clause of the U.S. Constitution, which makes federal law the supreme law of the land. When a state law genuinely conflicts with federal law, the state law gives way.
In drug cases, manufacturers usually argue "implied conflict preemption." Wyeth's version went like this: it couldn't satisfy both the Vermont jury's demand for a stronger warning and the federal rules governing drug labels, because the FDA had already approved the Phenergan label as written. Penalizing the company for that approved label, Wyeth said, conflicted with federal authority. In plain terms, the company argued that state juries shouldn't be allowed to second-guess the FDA's expert judgment.
Why FDA approval did not shield the manufacturer
The Court looked closely at the federal regulations and found the flaw in that argument. The FDA approves a drug's initial label, yes, but the regulations also account for the reality that new dangers surface after a drug has been used by a far larger population than any trial.
That's the purpose of the "changes being effected" (CBE) rule. It lets a manufacturer strengthen a warning label on its own, to improve safety, before getting formal FDA sign-off. Because Wyeth could have used the CBE process to beef up the IV-push warning without waiting for the agency, complying with both federal law and Vermont's state-law duty was not impossible. The whole conflict-preemption theory collapsed on that point.
As Justice Stevens put it for the majority, it has remained a central premise of federal drug regulation that the manufacturer, not the FDA, bears responsibility for its label at all times.
The Supreme Court's ruling in Wyeth v. Levine
Justice John Paul Stevens wrote the majority opinion, joined by Justices Kennedy, Souter, Ginsburg, and Breyer. The Court held that Congress did not intend to wipe out state-law failure-to-warn suits when it built the federal drug-regulation system. State tort law, the Court reasoned, works alongside federal regulation rather than against it. The Court concluded that state-law failure-to-warn duties can coexist with federal drug-labeling requirements when manufacturers retain the ability to strengthen warnings under FDA regulations.
Wyeth tried to lean on a 2006 FDA preamble in which the agency claimed that state failure-to-warn suits interfered with its work. The Court declined to defer to it. That statement lacked the force of law, reversed the FDA's own long-held position, and had been issued without giving the public a chance to comment. The Court affirmed the Vermont ruling, and Diana Levine kept her award.
Although Wyeth remains one of the most influential prescription-drug decisions in modern product liability law, it did not eliminate preemption defenses entirely. Later Supreme Court decisions reached different conclusions in certain generic-drug cases, where federal regulations may limit a manufacturer's ability to independently change labeling. As a result, whether a pharmaceutical claim is preempted often depends on the type of drug involved and the specific facts of the case.
How failure-to-warn claims apply to prescription drug cases
When a medication injures someone, the claim usually falls under product liability law, which covers three kinds of defects: design defects, manufacturing defects, and marketing defects. A marketing defect is what most people mean by "failure to warn."
Drug companies generally have a duty to provide adequate warnings regarding known risks associated with their products, primarily through warnings directed to prescribing healthcare providers. If a manufacturer knows, or reasonably should know, that a drug carries a serious danger, it has to say so clearly. When it fails to give adequate instructions for safe use, or leaves out a warning about a dangerous complication, it can be held responsible for the harm that follows. Most drug injury claims trace back to one of these common product liability defects, each with its own way of being proven.
Strict liability vs. negligence in drug cases
Depending on state law, failure-to-warn claims may proceed under strict liability, negligence principles, or both. Under strict liability, you don't have to prove the manufacturer was careless. You have to show the warning was defective or inadequate and that the defect caused your injury.
A negligence claim is different. It requires showing the company breached a duty of care, for instance, if its researchers knew about a serious complication and the company buried the data to protect sales. In Levine's case, the Vermont jury found that Wyeth's inadequate warning was both negligent and made Phenergan a defective product. A missing or weak warning can be grounds for a failure-to-warn lawsuit on its own, even when the product itself worked exactly as designed.
When can drug manufacturers still be sued after FDA approval?
After Wyeth, FDA approval is best understood as the starting line for safety monitoring, not the finish. Manufacturers can be, and often are, sued when they drop their post-market responsibilities.
A company has to track adverse event reports once a drug is in wide use. If a pattern of dangerous side effects emerges, it can't just point back to the original approval and sit still. It has to investigate and use the CBE process to update the warning. When evidence shows a manufacturer failed to adequately investigate emerging safety concerns, delayed warning updates, or withheld material safety information, injured patients may have grounds to pursue a claim.
The impact of Wyeth v. Levine on modern litigation
The decision still shapes courtrooms today. By refusing to hand drug companies blanket immunity, the Court kept the civil justice system working as a check on corporate negligence.
The ruling also acknowledged something practical: the FDA, expert as it is, has limited resources and can't perfectly police every drug on the market at all times. State lawsuits fill part of that gap. They surface hidden dangers, pull internal company documents into the open through discovery, and give manufacturers a financial reason to put patient safety ahead of revenue. Winning one often comes down to expert testimony in a product liability case establishing what the company knew and when it knew it.
What should patients know about dangerous drug injury claims?
If a prescription drug seriously harmed you or someone you love, don't assume your options are closed just because the drug is common or government-approved. Wyeth v. Levine makes clear that approval is not a liability shield.
These cases are demanding. They take detailed medical evidence, expert testimony, and a working command of both federal regulation and state law, and drug companies defend them hard with deep legal benches. If you suspect a medication caused your injury, save your medical records, keep any remaining medication in its original packaging, and talk to a lawyer sooner rather than later. Every state sets a statute of limitations, a deadline for filing, and missing it can end a valid claim before it starts.
Frequently asked questions
Does FDA approval protect a drug company from being sued? No. Under Wyeth v. Levine, FDA approval of a drug's label does not automatically preempt a state-law claim that the warning was inadequate. The manufacturer keeps primary responsibility for its label.
What is the "changes being effected" (CBE) rule? It's an FDA regulation that lets a manufacturer strengthen a drug's warning on its own, to improve safety, before the agency formally approves the change. Because this option exists, companies usually can't claim it was impossible to provide a stronger warning.
Can I still sue if my drug injury happened recently? Possibly, but deadlines matter. Each state has a statute of limitations on dangerous drug and product liability claims. Because the clock is already running, it's worth speaking with a product liability attorney promptly to protect your rights.
Call Brandon J. Broderick For Legal Help
Going up against a multibillion-dollar pharmaceutical company is daunting, but you don't have to do it alone. At Brandon J. Broderick, Attorney at Law, our team works to hold negligent corporations accountable for the harm their products cause. We understand what a dangerous drug injury does to a person and their family, physically, emotionally, and financially.
Our firm has the resources and experience to investigate complex product liability claims, dig into corporate conduct, and pursue full compensation for what you've lost. If a defective drug or an inadequate warning changed your life, reach out. Contact Brandon J. Broderick, Attorney at Law today for a free, no-obligation consultation. We'll listen, evaluate your case, and help you decide the best path forward.
Case citation: Wyeth v. Levine, 555 U.S. 555 (2009). The full opinion is available through the U.S. Supreme Court via Justia.